Resveratrol, a known SIRT1 activator, can counteract ANIT-induced cholestatic liver injury mainly by regulating BA homeostasis and reducing hepatic inflammation, both of which are regulated in an FXR-dependent manner, thereby contributing to amelioration of cholestasis (Ding et al., 2018). This evidence concerns the gene SIRT1 and cholestasis.